The NKG2 A/NKG2 B Type II Integral Membrane Protein pipeline drugs market research report outlays comprehensive information on the NKG2 A/NKG2 B Type II Integral Membrane Protein targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the NKG2 A/NKG2 B Type II Integral Membrane Protein pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

Smarter leaders trust GlobalData

The report also covers products from therapy areas such as Oncology, and Infectious Disease which include the indications Solid Tumor, Unspecified Cancer, Human Immunodeficiency Virus (HIV) Infections (AIDS), and Coronavirus Disease 2019 (COVID-19). It also reviews key players involved in NKG2 A/NKG2 B Type II Integral Membrane Protein targeted therapeutics development with respective active and dormant or discontinued products.

The NKG2 A/NKG2 B Type II Integral Membrane Protein pipeline targets constitutes close to 13 molecules. Out of which, approximately 12 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 2, 2, 1, 1, 4, and 2 respectively. Similarly, the universities portfolio in Discovery comprises 1 molecule.

NKG2 A/NKG2 B Type II Integral Membrane Protein overview

NKG2A and NKG2B (Natural Killer Group 2 member A and member B) are related type II integral membrane proteins that are part of the C-type lectin-like receptor family. These proteins play a role in the regulation of natural killer (NK) cell function and are involved in immune responses.

For a complete picture of NKG2 A/NKG2 B Type II Integral Membrane Protein’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.